🛰️ Daily AI Frontier
‹ back to 2026-08-26

Nature | 是卫士,还是内应?抑癌蛋白Rb的“双面人生”

Research Medical/Healthcare AI

Ranking

Overall 67
Content 70
Popularity 60

Observed public metrics from 1 member.

Representative image for Nature | 是卫士,还是内应?抑癌蛋白Rb的“双面人生”

Merged summary

TL;DR - A Nature study shows that the Rb tumor suppressor has a dual role in HR+ breast cancer: CDK4/6 inhibition activates Rb to suppress cell-cycle genes but also drives estrogen-responsive, pro-proliferative transcription. This mechanism explains both the benefit of combining CDK4/6 inhibitors with anti-estrogen therapy and reduced efficacy in ESR1-mutant tumors.

  • CUT&RUN mapping revealed that activated, hypophosphorylated Rb relocates to promoters and enhancers, joining ER-enriched 3D transcriptional hubs that activate genes such as CCND1.
  • CRISPR disruption of Rb-bound enhancers and RB1 knockout eliminated drug-induced estrogen-response gene activation, supporting a direct regulatory role.
  • Rb interacts with ER and KDM5A, counteracting KDM5A-mediated repression and expanding H3K4me3 across ER target genes.
  • Fulvestrant blocked this proliferative feedback in endocrine-sensitive models; in ESR1-mutant models, degrading mutant ER restored stronger cell-cycle suppression.

Sources (1)

Nature | 是卫士,还是内应?抑癌蛋白Rb的“双面人生”

WeChat: BioArt 2026-08-25 doi:10.1038/s41586-026-10886-w
Public signals OpenAlex citations 2
Providers: Hugging Face · N/A OpenAlex · Citations 2 Publisher · N/A Semantic Scholar · N/A X · N/A Fetched 2026-09-25 14:28:21.439801 UTC

TL;DR - A Nature study shows that the Rb tumor suppressor has a dual role in HR+ breast cancer: CDK4/6 inhibition activates Rb to suppress cell-cycle genes but also drives estrogen-responsive, pro-proliferative transcription. This mechanism explains both the benefit of combining CDK4/6 inhibitors with anti-estrogen therapy and reduced efficacy in ESR1-mutant tumors.

  • CUT&RUN mapping revealed that activated, hypophosphorylated Rb relocates to promoters and enhancers, joining ER-enriched 3D transcriptional hubs that activate genes such as CCND1.
  • CRISPR disruption of Rb-bound enhancers and RB1 knockout eliminated drug-induced estrogen-response gene activation, supporting a direct regulatory role.
  • Rb interacts with ER and KDM5A, counteracting KDM5A-mediated repression and expanding H3K4me3 across ER target genes.
  • Fulvestrant blocked this proliferative feedback in endocrine-sensitive models; in ESR1-mutant models, degrading mutant ER restored stronger cell-cycle suppression.
item →